Latest & greatest articles for oxcarbazepine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on oxcarbazepine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on oxcarbazepine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for oxcarbazepine

1. Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.

Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. BACKGROUND: This is an updated version of the Cochrane Review previously published in 2013. This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment, up to 70% of individuals (...) with active epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.Worldwide, phenytoin is a commonly used antiepileptic drug. It is important to know how newer drugs, such as oxcarbazepine, compare with commonly used standard treatments. OBJECTIVES: To review the time to treatment failure, remission and first seizure with oxcarbazepine compared to phenytoin, when used as monotherapy in people

Cochrane2018

2. Oxcarbazepine

Oxcarbazepine Top results for oxcarbazepine - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for oxcarbazepine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

4. WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy.

WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy. BACKGROUND: Most people with epilepsy have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic drug, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarize the current evidence regarding oxcarbazepine when used as an add-on treatment for drug-resistant partial epilepsy. OBJECTIVES: To evaluate the effects of oxcarbazepine when (...) used as an add-on treatment for drug-resistant partial epilepsy. SEARCH METHODS: We searched the Cochrane Epilepsy Group's Specialized Register (28 March 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006), MEDLINE (1966 to March 2006). No language restrictions were imposed. We checked the reference lists of retrieved studies for additional reports of relevant studies. We also contacted Novartis (manufacturers of oxcarbazepine) and experts

Cochrane2016

5. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine

Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized (...) , double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A CRD summary The authors concluded that antiepileptic drugs may cause neurological adverse events in patients with drug resistant epilepsy, which can limit their use and impair treatment success; higher doses of oxcarbazepine were associated with more frequent adverse events. The evidence had several limitations and the findings were not weighed against drug

DARE.2013

8. Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions From: Published: 13 December 2012 Therapeutic area: and Risk of serious skin-related adverse drug reactions, including Stevens-Johnson syndrome (...) , occurring with carbamazepine may be increased in the presence of the HLA-A*3101 allele in patients of European descent or Japanese origin. Article date: December 2012 Carbamazepine (Tegretol) is an antiepileptic drug that is indicated for the treatment of generalised tonic clonic seizures. Carbamazepine is also licensed to treat the paroxysmal pain of trigeminal neuralgia and for the prophylaxis of manic-depressive psychosis in patients unresponsive to lithium therapy. Oxcarbazepine (Trileptal

MHRA Drug Safety Update2012

9. New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate

New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate Article Text

Evidence-Based Mental Health2010

10. Oxcarbazepine for refractory epilepsy: systematic review of the literature

Oxcarbazepine for refractory epilepsy: systematic review of the literature Oxcarbazepine for refractory epilepsy: systematic review of the literature Oxcarbazepine for refractory epilepsy: systematic review of the literature Saconato H, do Prado GF, dos Santos Puga ME, Atallah AN CRD summary The review found that oxcarbazepine was effective as an alternative treatment for refractory partial or generalised epilepsy in children and adults. Given the limited evidence base, limitations (...) in the review process and methodological flaws in the included studies, the authors' conclusion should be treated with caution. Authors' objectives To evaluate the effectiveness of oxcarbazepine for refractory partial or generalised epilepsy. Searching PubMed (1966 to July 2008), EMBASE, LILACS and Cochrane Central Register of Controlled Trials (CENTRAL) (2008) were searched for relevant studies in any language; search terms were reported. Reference lists from retrieved studies and relevant reviews were

DARE.2009

11. Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder in children and adolescents

Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder in children and adolescents Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder in children and adolescents | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder in children and adolescents Article Text Therapeutics Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder

Evidence-Based Mental Health2008

12. Oxcarbazepine in the maintenance treatment of bipolar disorder.

Oxcarbazepine in the maintenance treatment of bipolar disorder. BACKGROUND: Some studies have suggested that oxcarbazepine has a role in preventing episode recurrence in bipolar affective disorder. This review attempted to investigate the existing evidence from randomised controlled trials for its use in the maintenance treatment of this illness. OBJECTIVES: To review the efficacy of oxcarbazepine, relative to placebo and other agents, in the prevention of affective episodes of bipolar (...) affective disorder. The efficacy of oxcarbazepine was considered in terms of episode recurrence, general and social functioning. Adverse effects, overall acceptability to participants and mortality were also considered. SEARCH STRATEGY: CCDANCTR-Studies and CCDANCTR-References were searched on 7/11/2007. Medline, CENTRAL, EMBASE and PsycINFO were searched in March 2007. Specialist journals and conference proceedings were handsearched. Reference lists of relevant papers and major textbooks of affective

Cochrane2008

13. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors assessed five antiepileptic drugs. These were carbamazepine, gabapentin, lamotrigine, oxcarbazepine and topiramate. The drug dosages and preparations were used as they would be by a clinician in everyday practice. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population

NHS Economic Evaluation Database.2007

14. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. 17382827 2007 03 26 2007 04 05 2017 02 19 1474-547X 369 9566 2007 Mar 24 Lancet (London, England) Lancet The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. 1000-15 Carbamazepine (...) carbamazepine was deemed to be standard treatment, and they were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Primary outcomes were time to treatment failure, and time to 12-months remission, and assessment was by both intention to treat and per protocol. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN38354748. For time to treatment failure, lamotrigine was significantly better than carbamazepine (hazard

Lancet2007 Full Text: Link to full Text with Trip Pro

15. Oxcarbazepine

Oxcarbazepine Oxcarbazepine Oxcarbazepine Mitchell A Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell A. Oxcarbazepine. University HealthSystem Consortium (UHC). Drug Monograph. 2001 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new and emerging pharmaceuticals. Monographs are written by drug

Health Technology Assessment (HTA) Database.2001

16. Oxcarbazepine add-on for drug-resistant partial epilepsy.

Oxcarbazepine add-on for drug-resistant partial epilepsy. BACKGROUND: Most people with epilepsy have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic drug, but up to 30 % develop refractory epilepsy, especially those with partial seizures. In this review we summarise the current evidence regarding oxcarbazepine when used as an add-on treatment for drug-resistant partial epilepsy. OBJECTIVES: To evaluate the effects of oxcarbazepine when used (...) as an add-on treatment for drug-resistant partial epilepsy. SEARCH STRATEGY: We searched the Cochrane Epilepsy Group's trials register, the Cochrane Controlled Trials Register (Cochrane Library Issue 1, 2000), MEDLINE (January 1966 to December 1999) and reference lists of articles. We also contacted Novartis (manufacturers of oxcarbazepine) and experts in the field. SELECTION CRITERIA: Randomized, placebo-controlled, double-blind, add-on trials of oxcarbazepine in patients with drug-resistant partial

Cochrane2000